CA3021571C - Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors - Google Patents

Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors Download PDF

Info

Publication number
CA3021571C
CA3021571C CA3021571A CA3021571A CA3021571C CA 3021571 C CA3021571 C CA 3021571C CA 3021571 A CA3021571 A CA 3021571A CA 3021571 A CA3021571 A CA 3021571A CA 3021571 C CA3021571 C CA 3021571C
Authority
CA
Canada
Prior art keywords
substituted
unsubstituted
alkyl
nad
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3021571A
Other languages
English (en)
French (fr)
Other versions
CA3021571A1 (en
Inventor
Ryan DELLINGER
Troy Rhonemus
Mark Morris
Aron Erickson
Hadi Cassier
Marie E. Migaud
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chromadex Inc
Original Assignee
Chromadex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chromadex Inc filed Critical Chromadex Inc
Publication of CA3021571A1 publication Critical patent/CA3021571A1/en
Application granted granted Critical
Publication of CA3021571C publication Critical patent/CA3021571C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
CA3021571A 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors Active CA3021571C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662325264P 2016-04-20 2016-04-20
US62/325,264 2016-04-20
PCT/US2017/028673 WO2017184885A1 (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors

Publications (2)

Publication Number Publication Date
CA3021571A1 CA3021571A1 (en) 2017-10-26
CA3021571C true CA3021571C (en) 2023-01-03

Family

ID=60088650

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3021571A Active CA3021571C (en) 2016-04-20 2017-04-20 Use of nicotinic acid riboside or nicotinamide riboside derivatives, and reduced derivatives thereof, as nad+increasing precursors

Country Status (13)

Country Link
US (1) US10183036B2 (enExample)
EP (1) EP3445359B8 (enExample)
JP (3) JP7089480B2 (enExample)
KR (1) KR20190008246A (enExample)
CN (1) CN109640984A (enExample)
AU (2) AU2017254657A1 (enExample)
BR (1) BR112018071573A2 (enExample)
CA (1) CA3021571C (enExample)
ES (1) ES2948968T3 (enExample)
MX (1) MX393076B (enExample)
NZ (1) NZ747693A (enExample)
WO (1) WO2017184885A1 (enExample)
ZA (1) ZA201807736B (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017011788A1 (en) 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
KR102354784B1 (ko) 2015-08-05 2022-01-25 메트로 인터내셔널 바이오테크 엘엘씨 니코틴아미드 모노뉴클레오티드 유도체 및 그 용도
GB2542881B (en) 2015-10-02 2020-01-01 Carr Andrew Crystal forms of ß-nicotinamide mononucleotide
CN110662542B (zh) 2016-11-11 2025-04-08 英国贝尔法斯特女王大学 烟酰基核苷和还原的烟酰基核苷、其改性衍生物、其磷酸化的类似物、其腺苷二核苷酸共轭物、以及其新颖结晶形式的有效且可规模化的合成
US11633421B2 (en) 2016-11-29 2023-04-25 University Of Iowa Research Foundation Use of NAD precursors for improving maternal health and/or offspring health
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
EP3558312A4 (en) 2016-12-21 2021-01-13 Newsouth Innovations Pty Limited METHODS FOR INCREASING VASCULAR DENSITY
WO2018191771A1 (en) * 2017-04-18 2018-10-25 Victor Chang Cardiac Research Institute Detection and treatment of congenital malformations
EP3642214A2 (en) 2017-06-19 2020-04-29 Gangadhara Ganapati Nicotinamide riboside derivatives and their uses
US11180521B2 (en) 2018-01-30 2021-11-23 Metro International Biotech, Llc Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
US20210196742A1 (en) * 2018-05-22 2021-07-01 Jumpstart Fertility Pty Ltd Amino acid salts of nicotinic acid ribosides as anti-aging agents
EP3897666A2 (en) 2018-12-17 2021-10-27 Mitopower LLC Nicotinyl riboside compounds and their uses
BR112021016432A2 (pt) 2019-02-21 2021-11-09 Chromadex Inc Composição que compreende prills de cera, processo para produzir prills de cera, composição nutricional, alimento, bebida ou suplemento alimentar que compreende prills de cera, e composição que compreende microesferas encapsuladas
US11939348B2 (en) 2019-03-22 2024-03-26 Metro International Biotech, Llc Compositions comprising a phosphorus derivative of nicotinamide riboside and methods for modulation of nicotinamide adenine dinucleotide
WO2020245190A1 (en) * 2019-06-05 2020-12-10 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for the treatment/prevention of liver disease
WO2020245187A1 (en) * 2019-06-05 2020-12-10 Société des Produits Nestlé S.A. Reduced nicotinamideribosides for treating or preventing kidney disease
CA3141641A1 (en) * 2019-06-05 2020-12-10 Societe Des Produits Nestle S.A. Reduced nicotinamideribosides for treating/preventing skeletal muscle disease
CN110973260A (zh) * 2019-12-11 2020-04-10 杨力 一种含有烟酰胺核糖苷的牛奶及其制备方法与应用
US20230000888A1 (en) 2019-12-19 2023-01-05 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Nad-precursors and dietary restriction for treating age related medical conditions
EP4117678A1 (en) * 2020-03-09 2023-01-18 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of neurological diseases and conditions
US20230138327A1 (en) * 2020-03-09 2023-05-04 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of pancreatic diseases and conditions
WO2021180739A1 (en) * 2020-03-09 2021-09-16 Société des Produits Nestlé S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of viral and bacterial infections
US20230119002A1 (en) * 2020-03-09 2023-04-20 Societe Des Produits Nestle S.A. Compositions and methods containing reduced nicotinamide riboside for prevention and treatment of cardiovascular diseases and conditions
CN114561342B (zh) * 2020-11-27 2024-12-20 西安交通大学医学院第一附属医院 Nad信号通路激动剂在体外胚胎培养中的应用
CN112716969B (zh) * 2021-01-15 2022-11-29 江苏恒正合生命科学有限公司 治疗阿尔茨海默症的组合物及其制备方法、应用
US20240245714A1 (en) * 2021-05-05 2024-07-25 Societe Des Produits Nestle S.A. Composition and methods using combination of narh and nr to produce intracellular nicotinamide adenine dinucleotide (nad+)
BR112023024712A2 (pt) 2021-05-27 2024-02-15 Metro Int Biotech Llc Sólidos cristalinos de mononucleotídeo de ácido nicotínico e ésteres dos mesmos e métodos de fabricação e uso
EP4313067A4 (en) * 2021-06-18 2024-12-18 Mitopower LLC TREATMENT OF IMMUNITY-RELATED DISORDERS, RENAL DISORDERS, LIVER DISORDERS, HEMOLYTIC DISORDERS AND OXIDATIVE STRESS-RELATED DISORDERS USING NRH, NARH AND THEIR REDUCED DERIVATIVES
WO2023076804A1 (en) * 2021-10-27 2023-05-04 Elysium Health Inc. Methods for treatment of menopausal syndromes
JP7111878B1 (ja) 2021-10-27 2022-08-02 旭化成ファーマ株式会社 ニコチンアミドモノヌクレオチドの製造方法
WO2023150072A1 (en) 2022-02-01 2023-08-10 Sinclair David A Compositions and methods for the preservation of plant matter
JP2025505177A (ja) * 2022-02-04 2025-02-21 エリジウム ヘルス インコーポレーテッド リボースリンカーおよびその複合体
WO2024118503A1 (en) 2022-11-28 2024-06-06 Hongene Biotech Corporation Functionalized n-acetylgalactosamine analogs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7022680B2 (en) * 2002-05-30 2006-04-04 Albert Einstein College Of Medicine Of Yeshiva University Inhibitors of ADP-ribosyl transferases, cyclases, and hydrolases
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7927859B2 (en) 2003-08-22 2011-04-19 Rice University High molar succinate yield bacteria by increasing the intracellular NADH availability
CA2555675A1 (en) 2004-02-10 2005-08-25 Trustees Of Dartmouth College Nicotinamide riboside kinase compositions and methods for using the same
CN1964627B (zh) 2004-06-04 2011-10-19 华盛顿大学 治疗神经病变的方法和组合物
DK1957086T3 (en) 2005-11-18 2018-06-06 Cornell Res Foundation Inc NICOTINOYL RIBOSIDE COMPOSITIONS AND METHODS OF USE
GB201313465D0 (en) 2013-07-29 2013-09-11 Queens University Of The Belfast Methods of preparing nicotinamide riboside and derivatives thereof
MX394291B (es) 2013-10-30 2025-03-24 Chromadex Inc Composiciones de ribosido de nicotinamida para uso topico en el tratamiento de afecciones de la piel.
WO2015186114A1 (en) 2014-06-06 2015-12-10 Glaxosmithkline Intellectual Property (No.2) Limited Nicotinamide riboside analogs and pharmaceutical compositions and uses thereof
US10280190B2 (en) * 2015-03-16 2019-05-07 Chromadex, Inc. Nicotinic acid riboside or nicotinamide riboside compositions, reduced derivatives thereof, and the use thereof to enhance skin permeation in treating skin conditions
WO2017011788A1 (en) 2015-07-15 2017-01-19 Cornell University Syntheses, activities, and methods of use of dihydronicotinamide riboside derivatives
KR102354784B1 (ko) 2015-08-05 2022-01-25 메트로 인터내셔널 바이오테크 엘엘씨 니코틴아미드 모노뉴클레오티드 유도체 및 그 용도
CA3021022C (en) * 2016-04-14 2024-04-23 ChromaDex Inc. Use of nicotinamide riboside, nicotinic acid riboside, nicotinamide mononucleotide, and nicotinoyl compound derivatives in infant formula

Also Published As

Publication number Publication date
CN109640984A (zh) 2019-04-16
US20170304338A1 (en) 2017-10-26
BR112018071573A2 (pt) 2019-02-12
JP2019514874A (ja) 2019-06-06
CA3021571A1 (en) 2017-10-26
EP3445359B1 (en) 2023-06-07
AU2022221384C1 (en) 2023-08-03
EP3445359A1 (en) 2019-02-27
EP3445359B8 (en) 2023-09-06
MX2018012849A (es) 2019-08-29
AU2017254657A1 (en) 2018-11-15
US10183036B2 (en) 2019-01-22
JP2021176871A (ja) 2021-11-11
JP2023002685A (ja) 2023-01-10
MX393076B (es) 2025-03-24
ZA201807736B (en) 2020-05-27
WO2017184885A8 (en) 2023-08-24
NZ747693A (en) 2023-07-28
AU2022221384A1 (en) 2022-09-22
JP7493007B2 (ja) 2024-05-30
KR20190008246A (ko) 2019-01-23
ES2948968T3 (es) 2023-09-22
EP3445359C0 (en) 2023-06-07
EP3445359A4 (en) 2019-12-25
JP7089480B2 (ja) 2022-06-22
WO2017184885A1 (en) 2017-10-26
AU2022221384B2 (en) 2023-03-23

Similar Documents

Publication Publication Date Title
AU2022221384B2 (en) Use of Nicotinic acid Riboside or Nicotinamide Ribosite derivatives, and reduced derivatives thereof, as nad+ increasing precursors
US12433908B2 (en) Use of nicotinamide riboside, nicotinic acid riboside, and nicotinamide mononucleotide, reduced nicotinyl compounds, and nicotinoyl compound derivatives in infant formula for healthy development
US10934322B2 (en) B-vitamin and amino acid conjugates of nicotinoyl ribosides and reduced nicotinoyl ribosides, derivatives thereof, and methods of preparation thereof
AU2020224158B2 (en) Use of nicotinamide riboside, nicotinic acid riboside, reduced nicotinyl riboside compounds, and nicotinyl riboside compound derivatives in formulations
AU2019214858B2 (en) Nicotinamide riboside analogs, pharmaceutical compositions, and uses thereof
CA2696878A1 (en) Compositions and methods for treatment of mitochondrial diseases
HK40004710A (en) Use of nicotinic acid riboside or nicotinamide ribosite derivatives, and reduced derivatives thereof, as nad+increasing precursors
US20230295211A1 (en) Methods of producing crystalline beta nicotinamide riboside triacetate chloride

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20201113

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250411

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250411